Eyenovia (EYEN) Competitors $0.09 +0.00 (+1.84%) (As of 11:05 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EYEN vs. CVKD, CLDI, ACXP, PULM, TPST, CMMB, COCP, IBIO, SPRB, and GLYCShould you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include Cadrenal Therapeutics (CVKD), Calidi Biotherapeutics (CLDI), Acurx Pharmaceuticals (ACXP), Pulmatrix (PULM), Tempest Therapeutics (TPST), Chemomab Therapeutics (CMMB), Cocrystal Pharma (COCP), iBio (IBIO), Spruce Biosciences (SPRB), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical products" industry. Eyenovia vs. Cadrenal Therapeutics Calidi Biotherapeutics Acurx Pharmaceuticals Pulmatrix Tempest Therapeutics Chemomab Therapeutics Cocrystal Pharma iBio Spruce Biosciences GlycoMimetics Cadrenal Therapeutics (NASDAQ:CVKD) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do analysts recommend CVKD or EYEN? Cadrenal Therapeutics presently has a consensus price target of $18.00, indicating a potential upside of 25.87%. Eyenovia has a consensus price target of $2.00, indicating a potential upside of 2,025.40%. Given Eyenovia's higher possible upside, analysts plainly believe Eyenovia is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in CVKD or EYEN? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in CVKD or EYEN? Eyenovia received 168 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 64.68% of users gave Eyenovia an outperform vote. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesEyenoviaOutperform Votes17464.68% Underperform Votes9535.32% Does the media refer more to CVKD or EYEN? In the previous week, Eyenovia had 31 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 34 mentions for Eyenovia and 3 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.41 beat Eyenovia's score of 0.13 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eyenovia 0 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Is CVKD or EYEN more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. Cadrenal Therapeutics' return on equity of -142.95% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -142.95% -118.40% Eyenovia -114,639.41%-1,108.24%-139.36% Which has preferable earnings and valuation, CVKD or EYEN? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$6.68-2.14EyenoviaN/AN/A-$27.26M-$0.73-0.13 Which has more volatility and risk, CVKD or EYEN? Cadrenal Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. SummaryCadrenal Therapeutics beats Eyenovia on 9 of the 16 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Eyenovia News Delivered to You Automatically Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EYEN vs. The Competition Export to ExcelMetricEyenoviaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.03M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.134.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book1.5710.306.906.33Net Income-$27.26M$153.61M$118.83M$225.93M7 Day PerformanceN/A-1.73%-1.92%-0.96%1 Month PerformanceN/A-7.26%-3.75%1.06%1 Year PerformanceN/A31.10%31.37%26.59% Eyenovia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EYENEyenovia3.0191 of 5 stars$0.09+1.8%$2.00+2,025.4%-93.2%$6.03MN/A-0.1340Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeCVKDCadrenal Therapeutics1.683 of 5 stars$14.30-1.4%$18.00+25.9%N/A$23.74MN/A0.004Gap UpCLDICalidi Biotherapeutics2.5448 of 5 stars$2.13-7.0%$16.67+682.5%N/A$23.66M$50,000.000.0041Gap DownACXPAcurx Pharmaceuticals2.3848 of 5 stars$1.36-2.2%$12.00+782.4%-61.6%$22.97MN/A0.003Short Interest ↓Analyst RevisionNews CoverageGap UpPULMPulmatrix0.26 of 5 stars$6.15+9.4%N/A+210.5%$22.45M$7.30M-2.2820Analyst ForecastGap UpTPSTTempest Therapeutics2.2548 of 5 stars$0.89-1.3%$20.00+2,156.1%-76.2%$22.35MN/A-0.5920Analyst RevisionCMMBChemomab Therapeutics2.8753 of 5 stars$1.56-5.2%$7.33+371.6%+228.0%$22.33MN/A0.0020COCPCocrystal Pharma3.0393 of 5 stars$2.15+4.4%$7.00+225.6%+25.6%$21.87MN/A-1.1910Gap UpIBIOiBio1.3721 of 5 stars$2.29+4.6%$4.30+87.8%N/A$20.95M$220,000.000.00100Positive NewsGap UpSPRBSpruce Biosciences2.9764 of 5 stars$0.50+1.0%$4.00+708.1%-64.0%$20.44M$10.09M0.0020Gap DownGLYCGlycoMimetics3.442 of 5 stars$0.32-4.1%$10.00+3,058.6%-78.4%$20.41M$10,000.000.0050Gap Down Related Companies and Tools Related Companies CVKD Competitors CLDI Competitors ACXP Competitors PULM Competitors TPST Competitors CMMB Competitors COCP Competitors IBIO Competitors SPRB Competitors GLYC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EYEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyenovia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYEN Stock Alerts